invIOs to present progress across oncology pipeline during JP Morgan Week 2025 VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in...

invIOs to attend JP Morgan Week in San Francisco in January VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week...

invIOs to present at Biotech Showcase VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter...

Big3Bio Introduces Inaugural Sponsors and Partners of BioWeekSF SAN FRANCISCO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Big3Bio is proud to announce the leading industry organizations that have signed on as inaugural partners and sponsors of BioWeekSF, the site...